Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462056 · ClinicalTrials.gov registry record · Phase 1
Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis
A Phase 1 study of Cystic Fibrosis, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03462056: Completed Phase 1 study of Cystic Fibrosis, sponsored by Washington University School of Medicine.
NCT03462056 is a Phase 1 study of Cystic Fibrosis that has completed, run by Washington University School of Medicine. The registered enrollment target is 16 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03462056, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Children with cystic fibrosis require increased caloric intake to maintain appropriate growth, an important determinant of long-term outcomes. This study seeks to determine the feasibility of using a novel therapeutic food to promote weight gain and growth in children with cystic fibrosis.
Primary Outcome
Change in BMI Z-score
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Cystic Fibrosis Ready to Use Supplemental Food
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-05-17 |
| Est. Completion | 2019-06-14 |
| Phase | Phase 1 |
What the finished NCT03462056 record still lists
NCT03462056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Cystic Fibrosis Ready to Use Supplemental Food is the first listed.
NCT03462056 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03462056 about?
NCT03462056 is a clinical study titled "Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis". Children with cystic fibrosis require increased caloric intake to maintain appropriate growth, an important determinant of long-term outcomes. This study seeks to determine the feasibility of using a novel therapeutic food to promote weight gain and growth in children with cystic fibrosis.
What is the current status of trial NCT03462056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-05-17. Estimated completion is 2019-06-14.
What conditions does trial NCT03462056 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03462056?
The interventions under investigation include: Cystic Fibrosis Ready to Use Supplemental Food (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03462056?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03462056 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03462056's enrollment target sits among peer trials
16 140th of 169 higher than 26 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI